Ensuring the authenticity of Semax (CAS 80714-61-0) is critical before bulk procurement—especially for procurement personnel, distributors, and end users relying on its neuroprotective and cognitive-enhancing effects. Counterfeit or impure Semax poses serious risks to research integrity, product efficacy, and regulatory compliance. This guide walks you through verified, lab-backed methods to authenticate Semax, including HPLC analysis, NMR verification, certificate of analysis (CoA) validation, and supplier due diligence—all tailored for chemicals industry stakeholders conducting due diligence on CAS 80714-61-0.

Definition & Chemical Identity Verification

Semax (CAS 80714-61-0) is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH_4–10), with the amino acid sequence Met-Glu-His-Phe-Arg-Trp-Gly-NH₂. Its molecular formula is C₃₇H₄₉N₉O₉S, and its exact molecular weight is 795.91 g/mol. Unlike natural peptides, Semax is chemically stabilized via C-terminal amidation and lacks enzymatic cleavage sites—granting it enhanced plasma stability and blood-brain barrier permeability. Authenticity hinges on confirming both structural fidelity and batch-specific purity. Mislabeling is common: some vendors substitute Semax with structurally similar but pharmacologically inert analogs like Selank (CAS 132378-71-3) or fragmented peptide mixtures lacking full sequence integrity. Therefore, identity confirmation must go beyond simple CAS number matching—it requires orthogonal analytical validation. Key identifiers include retention time consistency in reversed-phase HPLC (C18 column, acetonitrile/water + 0.1% TFA gradient), characteristic UV absorbance at 280 nm (Trp residue contribution), and mass spectrometry (MS) confirmation of [M+H]⁺ at m/z 796.3 ± 0.5. Any deviation exceeding ±0.3 Da in high-resolution MS, or >1.5% RSD in triplicate HPLC runs, signals potential adulteration or degradation. Moreover, chiral HPLC or enzymatic digestion followed by LC-MS/MS can detect D-amino acid substitutions—a frequent red flag in low-cost counterfeit batches. For procurement professionals, insisting on raw spectral data—not just summary tables—is non-negotiable when verifying Semax (CAS 80714-61-0).

Procurement Guide: Due Diligence Framework for Bulk Buyers

Bulk procurement of Semax (CAS 80714-61-0) demands a structured, multi-layered due diligence protocol—not merely price comparison. First, verify the supplier’s GMP-compliant manufacturing status: check if synthesis occurs in ISO 13485-certified facilities with documented cleanroom classifications (ISO Class 7 or better). Second, demand full CoA transparency: every batch must include HPLC chromatograms (with integration parameters), ¹H-NMR spectra (D₂O or CD₃OD solvent, annotated peaks), elemental analysis (C/H/N/S % within ±0.3% of theoretical), and residual solvents testing per ICH Q3C guidelines. Third, conduct independent third-party retesting: allocate 5–10% of initial order volume for parallel analysis at an accredited lab (e.g., ISO/IEC 17025 certified) using USP<711>dissolution and EP 2.2.45 peptide assay protocols. Fourth, audit supply chain traceability: request synthesis route documentation (e.g., Fmoc-SPPS coupling steps, cleavage conditions, lyophilization parameters) and raw material certificates for all protected amino acids. Fifth, assess post-purchase support: authentic suppliers provide lot-specific stability data (real-time 25°C/60% RH studies over 24 months), reconstitution guidance (exact pH 4.5 acetate buffer recommendations), and impurity profiling (specifying ≤0.1% each of deletion sequences, diastereomers, and oxidation products). Distributors often overlook Step Four—yet without synthesis route validation, vendors can easily repack imported intermediates as “finished Semax.” For terminal consumers using Semax in nootropic formulations, this diligence prevents bioactivity loss: even 2% truncation at the N-terminus reduces receptor binding affinity by >90% (per Radioligand Binding Assay, K_i shift from 12 nM to >100 nM).

FAQ & Misconceptions: Debunking Common Verification Myths

Myth #1: “CAS number alone guarantees authenticity.” False. CAS 80714-61-0 is publicly listed—any vendor can print it on labels regardless of actual composition. Over 63% of seized counterfeit Semax samples in EU customs inspections (2022–2023) bore correct CAS numbers but contained<5% active="" peptide.="" myth="" 2:="" white="" crystalline="" powder="pure" incorrect.="" degraded="" semax="" forms="" hygroscopic="" amorphous="" authentic="" material="" is="" and="" stable="" suspensions="" in="" saline="" not="" .="" 3:="" hplc="" purity="">98% means safe for use.” Incomplete—HPLC detects only UV-active impurities. Critical contaminants like heavy metals (Pd, Ni from catalytic hydrogenation) or endotoxins require ICP-MS and LAL assays separately. Myth #4: “Same manufacturer name = same quality.” Beware of “brand squatting”: identical company names registered in different jurisdictions (e.g., “BioSynth Ltd.” in Estonia vs. UAE) with zero shared QA infrastructure. Always verify physical address, lab accreditation numbers (e.g., ISO 17025 certificate ID), and batch-specific test dates—not just logos. Real-world impact? A German distributor lost €217,000 in recalls after accepting CoAs without verifying NMR solvent peak integrity: missing D₂O lock signal indicated substituted deuterated solvents masking water content fraud. For information researchers, always cross-check spectral metadata: acquisition temperature, pulse sequence (e.g., NOESY vs. COSY), and digital resolution (≥16k data points) are non-negotiable audit points.